<p>Rates of overdose, mental health crises increased after dose tapering among patients prescribed stable, long-term, higher-dose opioid therapy</p>

<p>Money to be used by communities for addiction treatment, prevention services, and other significant costs associated with the epidemic</p>

<p>High-dose buprenorphine protocol well tolerated in patients with untreated opioid use disorder; no reports of respiratory depression or sedation</p>

<p>There are still considerable gaps in medication care, with Black enrollees having lower use than Whites</p>

<p>However, opioids still commonly dispensed, with high-risk prescribing practices suspected in young children</p>

<p>Less than 5 percent of prescribers account for half of all buprenorphine treatment in the country</p>

<p>Improvement seen in treatment satisfaction and several secondary end points for depot buprenorphine versus sublingual buprenorphine</p>

<p>Differences between the two trajectories persist in opioid fills, misuse beyond 12 months</p>

<p>8-mg dose of naloxone hydrochloride nasal spray now approved with 2-mg and 4-mg doses</p>